Syntara Limited (ASX:SNT) Expands Skin Scarring Program with SNT-9465
Syntara Limited (ASX:SNT) expands its skin scarring program with the new SNT-9465 drug, initiating Phase 1a/b trials in 2025.
Category: Healthcare
Chimeric Therapeutics Limited (ASX:CHM) Announces $3.2 Million Entitlement Offer
Chimeric Therapeutics Limited (ASX:CHM) announces a $3.2 million entitlement offer to fund its ongoing cell therapy clinical trials.
dorsaVi Ltd (ASX:DVL) Launches First-In-Class 3D Motion Analysis Test
dorsaVi Ltd (ASX:DVL) launches a groundbreaking 3D motion analysis test to reduce ACL injuries in athletes using advanced AI technology.
AVITA Medical (ASX:AVH) Announces New Manufacturing and Distribution Agreements
AVITA Medical (ASX:AVH) partners with Stedical Scientific to enhance production and distribution of PermeaDerm wound matrix.
Navigator Global Investments Limited (ASX:NGI) Acquires 23.5% Stake in 1315 Capital
Navigator Global Investments Limited (ASX:NGI) acquires a 23.5% stake in healthcare investment firm 1315 Capital.
Global Health Limited (ASX:GLH) Secures $1 Million Contract with Youturn
Global Health Limited (ASX:GLH) secures a $1 million contract with Youturn to enhance digital solutions for youth mental health services.
InhaleRx Limited (ASX:IRX) Executes Study Order for Phase 2 IRX-211 Trial
InhaleRx Limited (ASX:IRX) executes Study Order for Phase 2 IRX-211 trial targeting breakthrough cancer pain.
Proteomics International Laboratories Ltd (ASX:PIQ) Launches Promarker®D Test to Combat Diabetic Kidney Disease in Australia
Proteomics International (ASX:PIQ) launches PromarkerD, a predictive test for diabetic kidney disease, enhancing early diagnosis and intervention.
Telix Pharmaceuticals Limited (ASX:TLX) Completes Acquisition of FAP-targeting Theranostic Candidates
Telix Pharmaceuticals (ASX:TLX) completes acquisition of FAP-targeting theranostic candidates, expanding its oncology pipeline.
PolyNovo Limited (ASX:PNV) Announces Change of CEO
PolyNovo Limited (ASX:PNV) announces CEO transition with Dr Robyn Elliott appointed as Acting CEO as it seeks a permanent successor.